Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. The outbreak has affected almost every country in the world and is, therefore, considered a pandemic.
Many laboratories are engaged in developing a new vaccine to help stop the spread of the virus. In an effort to provide you with reliable, current information regarding COVID-19 our field of action, the development of new vaccines, we offer here some links you might find useful.
DCVMN Statement on TRIPS waiver
COVAX MARKET PLACE - Press Release
Article by GAVI: COVID-19 Vaccine Manufacturing: DCVMN’s contribution to the global scale-up
Global COVID-19 Supply Chain & Manufacturing Summit, March 8th and 9th, 2021
Global Covid-19 Vaccine Supply Chain Manufacturing Summit Press Release
Landscape of Current C19 Supply Chain Manufacturing Capacity
Landscape of Current C19 Supply Chain Manufacturing Capacity - Appendix
September, 2020 - ACT-Accelerator Economic Investment Case & Financial Requirements Sept-Dec 2020 (PDF)
September, 2020 - ACT-Accelerator Status Report & Plan Sept-Dec 2020 (PDF)
July 10, 2020 - ACT-Accelerator Investment Case of the COVID-19 pandemic (PDF)
DCVMN has created the DCVMN Covid-19 committee to support the EC whenever questions regarding Covid are received by GAVI, CEPI, WHO, etc.
List of members of the DCVMN COVID Committee (PDF file)
ToR Covid19 Committee approved (PDF file)
SAGE recommendations to AZ COVID vaccines->https://www.who.int/news/item/22-04-2021-statement-of-the-strategic-advisory-group-of-experts-%28sage%29-on-immunization-continued-review-of-emerging-evidence-on-astrazeneca-covid-19-vaccines
Article on Covid mutations-
https://www.cell.com/cell/pdf/S0092-8674%2820%2930820-5.pdf
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines-
https://www.sciencedirect.com/science/article/pii/S0264410X20308306#!
https://brightoncollaboration.us/
WHO
COVID-19 Vaccine Delivery Partnership Updates
Closing the vaccine equity gap for stronger health systems.
In January 2022, WHO, UNICEF and Gavi established the COVID-19 Vaccine Delivery Partnership to support vaccine delivery. It specifically provides urgent operational support to the 34 countries that were at or below 10% full vaccination coverage in January 2022 to progress towards national and global targets. The greatest benefits of this approach will come from prioritizing full vaccination and boosters for high-priority populations – older adults, healthcare workers, and persons with co-morbidities including immunocompromised persons.
Sign up for our email brief for hand-picked articles, news, and more.
POSITION OF "WRITER/EDITOR" for the COVID-19 Vaccine Delivery Partnership.
https://jobs.unicef.org/cw/en-us/job/553189?lApplicationSubSourceID=
See here the latest publication from ICMRA - Report on the review of regulatory flexibilities/agilities as implemented by National Regulatory Authorities during Covid-19 pandemic –December 2020
WHO response to the COVID-19 pandemic
WHO daily information on COVID-19 and current situation
WHO landscape of COVID-19 candidate vaccines
Key criteria for the ethical acceptability of COVID-19 human challenge studies (PDF)
WHO Target Product Profiles for COVID-19 Vaccines
WHO ethics framework for human challenge with SARS-Cov-2
Recent report from a WHO Advisory Group on the ethics framework
WHO list of guidelines relevant to COVID product development (PDF file)
This list provides examples of existing WHO guidance documents adopted by WHO Expert Committee on Biological Standardization, published in Technical Report Series (TRS) 1, that may provide useful guidance and information for the development, production and evaluation of candidate SARS-CoV-2 vaccines2. This list is not exhaustive but focused on evaluation of vaccines. Some guidelines may also be applicable for other COVID-19 interventions such as therapeutic products (e.g. antibodies).
COVID-19 vaccine generic Phase 3 protocol
COVAX
Acess here to all COVAX’s workshops website
"COVAX Facility: Information session with industry" ,12 August 2020. (PDF file)
The Gavi Covid Vaccine Advance Market Commitment (COVAX AMC) : AN INVESTMENT OPPORTUNITY (PDF)
HIC-VAC Call for proposals for public engagement projects (these must be linked to human challenge or vaccines). The closing date of the call is AUGUST 21st 2020, 5pm BST; al, the details and forms are here:
https://www.hic-vac.org/funding/public-engagement-awards
HIC-VAC open call for training funding, especially lab exchanges with our LMIC members. See our website for more information:
https://www.hic-vac.org/funding/training-funding
The Global Health Network site
Now including a global map of CHIM expertise – and a media monitoring tool https://mrcnetwork.wixsite.com/website
CEPI, the Coalition for Epidemic Preparedness and Innovation, also supports projects on COVID vaccines’ development.
More information at www.cepi.net and https://cepi.net/get_involved/cfps/
CEPI sponsored Meeting held in March 2020 on Enhanced Disease (YouTube video)
Other useful articles on novel COVID-19 vaccine candidates
- The COVID-19 vaccine development landscape
https://www.nature.com/articles/d41573-020-00073-5
- The race for coronavirus vaccines: a graphical guide
https://www.nature.com/articles/d41586-020-01221-y
- Building the supply chain…before the supply
https://www.gatesfoundation.org/TheOptimist/Articles/coronavirus-vaccine-development-gavi?utm_source=GF&utm_medium=LI
- COVID-19: massive impact on lower-income countries threatens more disease outbreaks
https://www.gavi.org/news/media-room/covid-19-massive-impact-lower-income-countries-threatens-more-disease-outbreaks
There are many vaccine trackers. A quick search yielded these examples:
- WHO technical reports - see Draft Landscape document
- Regulatory Focus
- Milkeninstitute
- Artis Ventures
The core protocol to enable the evaluation of candidate vaccines against COVID-19 is available clicking on this link.
Comments are welcome until Friday 1 May 2020, at 20:00 CET to this email: covid19@who.int
Only feedback sent to this email will be taken into consideration.
